Vessi Medical

Company Overview

Snapshot

Founded in June 2015 by Eyal Kochavi, Vessi Medical operates with 1–10 employees. The company has raised a total of $18.2 million across two funding rounds from six investors. In February 2024, Vessi Medical closed a Series A round for its innovative cryotherapy bladder cancer treatment.

Business overview

Vessi Medical is developing a novel approach for treating urological tissue, specifically focusing on superficial urological tissue using surface cryotherapy. Their technology employs extreme cold to freeze and destroy abnormal tissue. The Vessi Medical system comprises a stand-alone console and a disposable catheter, designed for insertion into the bladder using existing intravesical techniques. This minimally invasive cryotherapy solution offers a therapeutic alternative to traditional surgery, aiming to reduce costs and complications associated with current treatments. The company operates within the Health Tech & Life Sciences sector, with a focus on Medical Devices and Medical Treatment & Therapeutics, serving healthcare providers globally.

Strategic signal

In February 2024, Vessi Medical successfully closed a $16.5 million Series A funding round. This significant capital injection validates the company's innovative cryotherapy approach for bladder cancer treatment and provides crucial resources for advancing its clinical development and market entry. The completion of a first-in-human study with promising results further signals a strong trajectory towards commercialization and potential disruption in urological oncology.

Company Intelligence Q&A

What is Vessi Medical's core technology?

Vessi Medical develops a system that uses surface cryotherapy to treat superficial urological tissue by freezing and destroying abnormal cells. This minimally invasive approach is designed as an alternative to surgery for conditions like bladder cancer.

When did Vessi Medical complete its Series A funding round?

Vessi Medical closed its Series A funding round in February 2024. The round was led by ALIVE Israel Healthtech Fund and included participation from Agriline and The Trendlines Group.

What was a key development for Vessi Medical in early 2024?

In February 2024, Vessi Medical announced the closure of a $16.5 million Series A round for its innovative cryotherapy bladder cancer treatment. This followed the finalization of its first-in-human clinical study with promising results.

Which investors participated in Vessi Medical's Series A round?

Vessi Medical's Series A round in February 2024 saw participation from ALIVE Israel Healthtech Fund and Agriline, among others.

What was the outcome of Vessi Medical's first-in-human clinical study?

Vessi Medical finalized its first-in-human clinical study in 2023, reporting very promising results for its cryotherapy treatment of urological tissue.